NEW YORK (TheStreet) -- RATINGS CHANGES
AbbVie (ABBV - Get Report) was downgraded at Morgan Stanley to equal-weight from overweight. Twelve-month price target is $72. Stock is already pricing in potential for Hepatitis-C and Humira, Morgan Stanley said.
Advisory Board (ABCO) was upgraded at Stifel Nicolaus to buy from hold. Twelve-month price target is $47. Royall purchase should boost margins, Stifel Nicolaus said.
Ariad (ARIA) was downgraded at Credit Suisse to underperform from neutral. Twelve-month price target is $6. Launch metrics remain weak and any pricing benefit will likely be temporary, Credit Suisse said.
Eli Lilly (LLY - Get Report) was upgraded at Morgan Stanley to overweight from underweight. Twelve-month price target is $85. Prospects for the company's pipeline are undervalued, Morgan Stanley said.
Macerich (MAC) was downgraded at Deutsche Bank to hold from buy. Stock has run following disclosure of Simon Property Group (SPG) stake in company and appears fairly valued at a 4.6% implied cap rate, Deutsche Bank said.
Thompson Creek (TC) was downgraded at Deutsche Bank to hold from buy. Exiting moly business as prices fall, Deutsche Bank said. Twelve-month price target was cut to $1.60 from $3.75.
Toll Brothers (TOL - Get Report) was downgraded at RBC Capital to underperform from sector perform. Twelve-month price target is $30. Company has limited pricing power and will likely grow slower than its peers, RBC Capital said.
Editor's note: To see analysts' stock comments and changes to price targets and earnings estimates, go to "Street Notes," which is available only to Real Money subscribers. To find out how to become a subscriber, please click here.